Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 28, 2025 07:00 ET | Source: ONL Therapeutics

ONL Therapeutics Announces Randomization of First Patient in Global Phase 2 GALAXY Trial of Xelafaslatide (ONL1204) in Patients with Geographic Atrophy (GA) Associated with Dry AMD

ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
October 14, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001)100% of patients were off all topical IOP-lowering medications at 24 months100% of treated patients achieved 20/30 or...
September 16, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Appoints Anand Sundaram as Head of Commercial

ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced the appointment of Anand Sundaram as the company’s Vice President,...
September 04, 2025 10:00 ET | Source: Verified Market Research

Retinal Imaging Devices Market is expected to generate a revenue of USD 5.98 Billion by 2032, Globally, at 9% CAGR: Verified Market Research®

Lewes, Delaware, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Global Retinal Imaging Devices Market Size is projected to grow at a CAGR of 9% from 2026 to 2032, according to a new report published by...
August 20, 2025 10:02 ET | Source: Glaucoma Research Foundation (GRF)

Glaucoma Research Foundation Launches Treatment Accelerator with Transformative $5 Million Gift

SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Glaucoma Research Foundation is proud to announce it received a transformative $5 million gift from the John and Daria Barry Foundation, the largest...
August 19, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its...
July 31, 2025 05:27 ET | Source: Research and Markets

Glaucoma Global Clinical Trials Market Landscape Report 2025 Featuring Alcon, AbbVie, Santen Pharmaceutical, Pfizer, Kowa, Viatris, Merck, Novartis, Senju Pharmaceutical, Bausch Health

Dublin, July 31, 2025 (GLOBE NEWSWIRE) -- The "Glaucoma - Global Clinical Trials Review, 2025" has been added to ResearchAndMarkets.com's offering. The clinical trial report offers a...
July 08, 2025 09:24 ET | Source: Research and Markets

Glaucoma Therapeutics Market Outlook, Forecast Trends and Growth Analysis 2025-2034 | Companies are Obtaining Fast Track and Orphan Drug Designations for Revolutionary Treatments

Dublin, July 08, 2025 (GLOBE NEWSWIRE) -- The "Glaucoma Therapeutics Market Size and Share - Outlook Report, Forecast Trends and Growth Analysis (2025-2034)" has been added to ...
June 23, 2025 06:14 ET | Source: Research and Markets

Acute Ocular Pain Market Research 2025-2035: Screen Time and Digital Strain Surge Demand, Regional Players and Emerging Markets Propel Growth

Dublin, June 23, 2025 (GLOBE NEWSWIRE) -- The "Acute Ocular Pain Market - A Global and Regional Analysis: Focus on Indication and Region - Analysis and Forecast, 2025-2035" report has been added to ...
June 02, 2025 08:00 ET | Source: SpyGlass Pharma, Inc.

SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic...